Angiogenesis in gynecological oncology—mechanism of tumor progression and therapeutic targets
作者： K.K. RASILA , R.A. BURGER , H. SMITH , F.C. LEE , C. VERSCHRAEGEN
DOI: 10.1111/J.1525-1438.2005.00132.X
关键词:
摘要: The purpose of this article is to review the current literature pertaining various angiogenic stimulators and angiogenesis inhibitors in gynecological malignancies relevance these markers prognosis diseases. We also summarize antiangiogenic drugs currently development clinical use oncology. information was obtained from a computer search MEDLINE for studies published English language regarding between 1970 December 2003; additional sources were identified through cross-referencing. In ovarian cancer, different activators have been found correlate with microvessed density (MVD), stage, lymph node peritoneal metastasis, survival. cervical correlation has seen increased grade, tumor size, Studies endometriat cancer show MVD, Whereas, gestational trophoblastic neoplasm (GTD) only few studied, some correlated progression. Information on anti ongoing upcoming trials presented. Angiogenesis factors may prognostic role play patients cancers should continue be investigated as clinically useful markers. Antiangiogenic-targeted therapies offer an attractive strategy investigation gynecologic
elsevier.com
sci-hub.se 参考文章(131)
Sowter Hm, Charnock-Jones Ds, Clark De, Evans Al, Corps An, Smith Sk, Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Laboratory Investigation. ,vol. 77, pp. 607- 614 ,(1997)
Raffaele Landolfi, Sergio Storti, Francesco Sacco, Donata Scribano, Laura Cudillo, Giuseppe Leone, Platelet activation in patients with benign and malignant ovarian diseases. Tumori. ,vol. 70, pp. 459- 462 ,(1984) , 10.1177/030089168407000513
Roger von Moos, Silke Gillessen, Thomas Cerny, Rahel Stolz, Thalidomide: from tragedy to promise. Swiss Medical Weekly. ,vol. 133, pp. 77- 87 ,(2003) , 10.4414/SMW.2003.09947
D J Loskutoff, S Grancha, T Thinnes, F España, A Estellés, J Gilabert, J Aznar, M Chirivella, Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease American Journal of Pathology. ,vol. 149, pp. 1229- 1239 ,(1996)
G. K. Michalopoulos, R. Zarnegar, L. Oliver, H. K. Wolf, Hepatocyte growth factor in human placenta and trophoblastic disease. American Journal of Pathology. ,vol. 138, pp. 1035- 1043 ,(1991)
Marya F. McCarty, Diane Bielenberg, Cherrie Donawho, Corazon D. Bucana, Isaiah J. Fidler, Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms Clinical & Experimental Metastasis. ,vol. 19, pp. 609- 615 ,(2002) , 10.1023/A:1020923326441
S M Steinberg, M J Merino, M L Rothenberg, E C Kohn, H C Hollingsworth, Tumor angiogenesis in advanced stage ovarian carcinoma. American Journal of Pathology. ,vol. 147, pp. 33- 41 ,(1995)
Lei Yao, Sandra E. Pike, Joyce Setsuda, Justin Parekh, Ghanshyam Gupta, Mark Raffeld, Elaine S. Jaffe, Giovanna Tosato, Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12 Blood. ,vol. 96, pp. 1900- 1905 ,(2000) , 10.1182/BLOOD.V96.5.1900
Dieter Marmé, Joachim Drevs, Harald Hugenschmidt, Clemens Unger, Jeanette Wood, Georg Martiny-Baron, Helmut Madjar, Christine Wittig, Marianne Müller, Inga Hofmann, Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model Cancer Research. ,vol. 60, pp. 4819- 4824 ,(2000)
A Orpana, H Mänpää, K Alitalo, P Salven, H Joensuu, Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clinical Cancer Research. ,vol. 3, pp. 647- 651 ,(1997)